0000921895-24-000773.txt : 20240403 0000921895-24-000773.hdr.sgml : 20240403 20240403091334 ACCESSION NUMBER: 0000921895-24-000773 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240325 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lazar David E. CENTRAL INDEX KEY: 0001932843 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37367 FILM NUMBER: 24817045 MAIL ADDRESS: STREET 1: 5305 VIDA RESIDENCE STREET 2: MARSA CITY: DUBAI STATE: C0 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OPGEN INC CENTRAL INDEX KEY: 0001293818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 061614015 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-869-9683 MAIL ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 3 1 form312227017laz_04022024.xml OWNERSHIP DOCUMENT X0206 3 2024-03-25 0 0001293818 OPGEN INC OPGN 0001932843 Lazar David E. VILLA 1, 14-43RD STREET JUMEIRAH 2 DUBAI C0 00000 UNITED ARAB EMIRATES 1 1 1 0 Chief Executive Officer Common Stock 0 D Series E Convertible Preferred Stock 2024-03-25 Common Stock 4800000 D No shares of Common Stock are beneficially owned. On March 25, 2024, David E. Lazar (the "Reporting Person") and OpGen, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire an aggregate of 3,000,000 shares of the Company's Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a price of $1.00 per share. Each share of Series E Preferred Stock is convertible into 24 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on March 25, 2024, whereby the Reporting Person acquired 200,000 shares of Series E Preferred Stock for a total purchase price of $200,000. The Reporting Person will acquire additional shares of Series E Preferred Stock at subsequent closings. The Series E Preferred Stock is perpetual and therefore has no expiration date. The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. /s/ David E. Lazar 2024-04-03